|
20 Mar 2019 |
Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
|
|
20 Mar 2019 |
PDC*line Pharma enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia
|
|
20 Mar 2019 |
SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer
|
|
20 Mar 2019 |
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
|
|
19 Mar 2019 |
Allergy Therapeutics announces top-line Phase III results from its B301 clinical trial
|
|
19 Mar 2019 |
Amphera Recruits First Patients to Pivotal Phase II/III study of MesoPher to Treat Pleural Mesothelioma
|
|
19 Mar 2019 |
IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
|
|
19 Mar 2019 |
China National Biotec Group (CNBG) and ImmunoBiology Ltd Enter Licensing Agreement to Co-Develop Next Generation Vaccine against Pneumococcal Disease in Greater China
|
|
19 Mar 2019 |
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
|
|
06 Mar 2019 |
Transgene to start clinical development of lead myvacTM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
|
|
04 Mar 2019 |
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
|
|
02 Mar 2019 |
Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
|
|
02 Mar 2019 |
Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
|
|
28 Feb 2019 |
Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization
|
|
15 Feb 2019 |
New Clinical Data Analysis Shows Survival Benefit Three Years after Treatment with Sipuleucel-T
|
|
14 Feb 2019 |
Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer
|
|
13 Feb 2019 |
Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
|
|
13 Feb 2019 |
Affinivax, Inc. Announces Initiation of Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas
|
|
12 Feb 2019 |
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus
|
|
04 Feb 2019 |
VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine
|
|
31 Jan 2019 |
Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
|
|
30 Jan 2019 |
Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents
|
|
29 Jan 2019 |
Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
|
|
24 Jan 2019 |
Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests
|
|
24 Jan 2019 |
Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine
|
